A Phase 3 interventional study of lamictal in Epilepsy, sponsored by GlaxoSmithKline. Completed at 2 sites in Japan. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-09-26.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing lamotrigine in Epilepsy — 2 open to participants now, 2 under way, none of them phase 3. Lamotrigine · Epilepsy.
Among the 36 studies testing lamotrigine in Epilepsy, this one is the 17th largest by enrollment, is one of 5 that started in 2006, is one of 12 in phase 3, and was the 15th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 36 studies testing lamotrigine in Epilepsy are open now. Recruiting first, the newest first:
Assiut University
Ages 2–12 · Healthy volunteers
National Taiwan University Hospital
Ages 20+
Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 2 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 76 across the 36 interventional studies. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
54 studies in Epilepsy by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 53 finished, 23 (43%) have results posted.
Among the 54 studies in Epilepsy by GlaxoSmithKline, this one is the 18th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2006, is one of 18 in phase 3, and was the 17th registered.
GlaxoSmithKline’s Epilepsy studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing lamotrigine in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 54 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate safety information of BW430C when administered using the lower starting doses and slower dose escalations as recommended Global Data Sheet
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: lamictal
anti-epileptic drug
Number of Participants With Any Rash Event (Including Stevens-Johnson Syndrome [SJS] and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment
Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing "rash"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the "Skin and Subcutaneous Tissue Disorders" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.
Time frame: 8 weeks
Number of Rash Events Experienced (Including SJS and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment
Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing "rash"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the "Skin and Subcutaneous Tissue Disorders" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.
Time frame: 8 weeks
Number of Participants With the Indicated Intensity of Rash (Including SJS and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment
The rash events (including SJS and any other serious drug eruption) were classified into severe (rash prevents participant from leading a normal life), moderate (participant's discomfort due to rash interferes with daily life), and mild (no interference with participant's daily life due to rash), based on the intesity of the event.
Time frame: 8 weeks
Number of Drug-related and Not Related Rash Events (Including SJS and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment
The adverse event of rash was considered to be drug-related when the Investigator answered "Yes" to the following question: "Is there a reasonable possibility that the adverse event may have been caused by the investigational product?".
Time frame: 8 weeks
Percentage of Participants With at Least a 50 Percent Reduction in Seizure Frequency for the Indicated Types of Seizures
Partial seizures are seizures that affect only a part of the brain at onset. Tonic-clonic seizures (grand mal seizures) affect the entire brain and are characterized by a generalized involuntary muscular contraction and cessation of respiration followed by tonic and clonic spasms of the muscles. Lennox-Gastaut syndrome (LGS) is a pediatric epilepsy syndrome characterized by multiple seizure types; mental retardation or regression; and abnormal findings on an electroencephalogram (EEG), with paroxysms of fast activity and generalized slow spike-and-wave discharges.
Time frame: 8 weeks
Percent Change in Seizure Frequency of the Indicated Types of Seizures
Percent change in seizure frequency was calculated as 100 \* (pre-treatment seizures minus MP seizures)/pre-treatment seizures. Partial seizures are seizures that affect only a part of the brain at onset. Tonic-clonic seizures (grand mal seizures) affect the entire brain and are characterized by a generalized involuntary muscular contraction and cessation of respiration followed by tonic and clonic spasms of the muscles. Lennox-Gastaut syndrome (LGS) is a pediatric epilepsy syndrome characterized by multiple seizure types, mental retardation or regression, and abnormal findings on an ECG.
Time frame: Pre-treatment (Day 0) and Week 8 of the Maintenance Phase (Study Week 14)
Number of Participants With Any Rash Event (Including SJS and Any Other Serious Drug Eruption) up to the End of the Maintenance Phase
Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing "rash"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the "Skin and Subcutaneous Tissue Disorders" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.
Time frame: Up to Week 8 of the Maintenance Phase (Study Week 14)
Number of Rash Events Experienced (Including SJS and Any Other Serious Drug Eruption) up to the End of the Maintenance Phase
Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing "rash"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the "Skin and Subcutaneous Tissue Disorders" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.
Time frame: Up to Week 8 of the Maintenance Phase (Study Week 14)
Number of Participants With the Indicated Intensity of Rash (Including SJS and Any Other Serious Drug Eruption) up to the End of the Maintenance Phase
The rash events (including SJS and any other serious drug eruption) were classified into severe (rash prevents participant from leading a normal life), moderate (participant's discomfort due to rash interferes with daily life), and mild (no interference with participant's daily life due to rash), based on the intesity of the event.
Time frame: Up to Week 8 of the Maintenance Phase (Study Week 14)
Number of Drug-related and Not Related Rash Events (Including SJS and Any Other Serious Drug Eruption) up to the End of the Maintenance Phase
The adverse event of rash was considered to be drug-related when the Investigator answered "Yes" to the following question: "Is there a reasonable possibility that the adverse event may have been caused by the investigational product?".
Time frame: Up to Week 8 of the Maintenance Phase (Study Week 14)
Number of Rash Events (Including SJS and Any Other Serious Drug Eruption) Adjudicated by the Rash Adjudication Committee in Participants Taking VPA
The rash adjudication committee reviewed all rash events from a dermatologic standpoint based on the nature, onset site, affected area, time to onset, outcome, and the investigator's comments to adjudicate whether or not the reported event was a drug eruption. A drug eruption is an eruption or a solitary lesion caused by a drug taken internally, often a result of allergic sensitization.
Time frame: Up to Week 8 of the Maintenance Phase (Study Week 14)
Percentage of Participants With Monocyte Values Outside the Normal Range (Shifted High) at Weeks 4 and 8
Monocytes are a type of white blood cell (WBC; typically comprising 2%-8% of total WBCs) and are a part of the immune system. The normal range for adults is 0.2 to 0.95 \* 10\^3 cells per microliter (µL); the normal range for adolescents is 0 to 0.8 \* 10\^3 cells per µL. The monocyte count may increase during chronic inflammation, stress response, immune-mediated disease, viral fever, etc. The percentage of participants (par.) with monocyte values outside the normal range was calculated as 100 \* (number of par. with monocyte values outside the normal range) divided by the total number of par.
Time frame: Week 4 and Week 8
| Milestone | Adults: LTG | Adolescents: LTG |
|---|---|---|
| Started | 51 | 51 |
| Completed | 50 | 49 |
| Not completed | 1 | 2 |
| Withdrew: Adverse event | 1 | 2 |
| Milestone | Adults: LTG | Adolescents: LTG |
|---|---|---|
| Started | 49 | 48 |
| Completed | 34 | 35 |
| Not completed | 15 | 13 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lack of efficacy | 12 | 11 |
| Withdrew: Withdrawal due to wishes of family | 1 | 0 |
| Withdrew: Poor compliance | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 |
Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing "rash"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the "Skin and Subcutaneous Tissue Disorders" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.
| participants | Adults: LTG | Adolescents: LTG | Total: LTG |
|---|---|---|---|
| Number of Participants With Any Rash Event (Including Stevens-Johnson Syndrome [SJS] and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment | 2 | 3 | 5 |
Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing "rash"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the "Skin and Subcutaneous Tissue Disorders" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.
| rash events | Adults: LTG | Adolescents: LTG | Total: LTG |
|---|---|---|---|
| Number of Rash Events Experienced (Including SJS and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment | 3 | 4 | 7 |
The rash events (including SJS and any other serious drug eruption) were classified into severe (rash prevents participant from leading a normal life), moderate (participant's discomfort due to rash interferes with daily life), and mild (no interference with participant's daily life due to rash), based on the intesity of the event.
| participants | Total: LTG |
|---|---|
| Severe | 0 |
| Moderate | 2 |
| Mild | 3 |
The adverse event of rash was considered to be drug-related when the Investigator answered "Yes" to the following question: "Is there a reasonable possibility that the adverse event may have been caused by the investigational product?".
| rash events | Total: LTG |
|---|---|
| Drug related | 3 |
| Not related to drug | 4 |
Partial seizures are seizures that affect only a part of the brain at onset. Tonic-clonic seizures (grand mal seizures) affect the entire brain and are characterized by a generalized involuntary muscular contraction and cessation of respiration followed by tonic and clonic spasms of the muscles. Lennox-Gastaut syndrome (LGS) is a pediatric epilepsy syndrome characterized by multiple seizure types; mental retardation or regression; and abnormal findings on an electroencephalogram (EEG), with paroxysms of fast activity and generalized slow spike-and-wave discharges.
| percentage of participants | Adults: LTG | Adolescents: LTG | Total: LTG |
|---|---|---|---|
| All Partial Seizures, n=28, 25, 53 | 17.9 | 20.0 | 18.9 |
| Tonic-clonic Seizures, n=5, 4, 9 | 60.0 | 0 | 33.3 |
| Generalized Seizures with LGS, n=25, 25, 50 | 16.0 | 20.0 | 18.0 |
Percent change in seizure frequency was calculated as 100 \* (pre-treatment seizures minus MP seizures)/pre-treatment seizures. Partial seizures are seizures that affect only a part of the brain at onset. Tonic-clonic seizures (grand mal seizures) affect the entire brain and are characterized by a generalized involuntary muscular contraction and cessation of respiration followed by tonic and clonic spasms of the muscles. Lennox-Gastaut syndrome (LGS) is a pediatric epilepsy syndrome characterized by multiple seizure types, mental retardation or regression, and abnormal findings on an ECG.
| percent change | Adults: LTG | Adolescents: LTG | Total: LTG |
|---|---|---|---|
| All Partial Seizures, n=28, 25, 53 | 6.3 (-44.8 to 28.7) | -11.1 (-46.6 to 34.6) | -9.8 (-42.3 to 28.6) |
| Tonic-clonic Seizures, n=5, 4, 9 | 83.3 (NA to NA) | 27.4 (NA to NA) | 36.5 (-47.9 to 100.0) |
| Generalized Seizures with LGS, n=25, 25, 50 | 18.6 (-16.2 to 32.2) | 10.1 (-24.9 to 28.8) | 12.4 (5.8 to 27.6) |
Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing "rash"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the "Skin and Subcutaneous Tissue Disorders" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.
| participants | Adults: LTG | Adolescents: LTG | Total: LTG |
|---|---|---|---|
| Number of Participants With Any Rash Event (Including SJS and Any Other Serious Drug Eruption) up to the End of the Maintenance Phase | 2 | 3 | 5 |
Any rash event (including SJS or any other serious drug eruption) includes: all event terms containing "rash"; drug eruption; SJS; toxic epidermal necrolysis; rash generalized; and events grouped into the "Skin and Subcutaneous Tissue Disorders" system organ class per the Medical Dictionary for Regulatory Activities (MedDRA), including the above-mentioned events that the GSK medical advisors judged to be included as any rash event. SJS, also called as erythema multiforme, is a skin disorder resulting from an allergic reaction or infection.
| rash events | Adults: LTG | Adolescents: LTG | Total: LTG |
|---|---|---|---|
| Number of Rash Events Experienced (Including SJS and Any Other Serious Drug Eruption) up to the End of the Maintenance Phase | 3 | 4 | 7 |
The rash events (including SJS and any other serious drug eruption) were classified into severe (rash prevents participant from leading a normal life), moderate (participant's discomfort due to rash interferes with daily life), and mild (no interference with participant's daily life due to rash), based on the intesity of the event.
| participants | Total: LTG |
|---|---|
| Severe | 0 |
| Moderate | 2 |
| Mild | 3 |
The adverse event of rash was considered to be drug-related when the Investigator answered "Yes" to the following question: "Is there a reasonable possibility that the adverse event may have been caused by the investigational product?".
| rash events | Total: LTG |
|---|---|
| Drug related | 3 |
| Not related to drug | 4 |
The rash adjudication committee reviewed all rash events from a dermatologic standpoint based on the nature, onset site, affected area, time to onset, outcome, and the investigator's comments to adjudicate whether or not the reported event was a drug eruption. A drug eruption is an eruption or a solitary lesion caused by a drug taken internally, often a result of allergic sensitization.
| adjudicated rash events | Adults: LTG | Adolescents: LTG | Total: LTG |
|---|---|---|---|
| Number of Rash Events (Including SJS and Any Other Serious Drug Eruption) Adjudicated by the Rash Adjudication Committee in Participants Taking VPA | 1 | 2 | 3 |
Monocytes are a type of white blood cell (WBC; typically comprising 2%-8% of total WBCs) and are a part of the immune system. The normal range for adults is 0.2 to 0.95 \* 10\^3 cells per microliter (µL); the normal range for adolescents is 0 to 0.8 \* 10\^3 cells per µL. The monocyte count may increase during chronic inflammation, stress response, immune-mediated disease, viral fever, etc. The percentage of participants (par.) with monocyte values outside the normal range was calculated as 100 \* (number of par. with monocyte values outside the normal range) divided by the total number of par.
| percentage of participants | Total: LTG |
|---|---|
| Week 4 | 15.2 |
| Week 8 | 16.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adults: LTG | — | 5/51 (9.8%) | 48/51 (94.1%) |
| Adolescents: LTG | — | 2/51 (3.9%) | 50/51 (98%) |
| Total: LTG | — | 7/102 (6.9%) | 98/102 (96.1%) |
| Event | Adults: LTG | Adolescents: LTG | Total: LTG |
|---|---|---|---|
| SleepinessNervous system disorders | 1/51 | 0/51 | 1/102 |
| PyrexiaGeneral disorders | 0/51 | 1/51 | 1/102 |
| Drug eruptionSkin and subcutaneous tissue disorders | 0/51 | 1/51 | 1/102 |
| Status epilepticusNervous system disorders | 1/51 | 0/51 | 1/102 |
| PneumoniaInfections and infestations | 1/51 | 0/51 | 1/102 |
| VomitingGastrointestinal disorders | 1/51 | 0/51 | 1/102 |
| Aleviatin (phenytoin) poisoningInjury, poisoning and procedural complications | 1/51 | 0/51 | 1/102 |
| Frequent convulsionsNervous system disorders | 0/51 | 1/51 | 1/102 |
| Event | Adults: LTG | Adolescents: LTG | Total: LTG |
|---|---|---|---|
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 5/51 | 15/51 | 20/102 |
| NasopharyngitisInfections and infestations | 10/51 | 14/51 | 24/102 |
| SomnolenceNervous system disorders | 7/51 | 11/51 | 18/102 |
| DiarrhoeaGastrointestinal disorders | 3/51 | 11/51 | 14/102 |
| DizzinessNervous system disorders | 10/51 | 2/51 | 12/102 |
| Arthropod stingInjury, poisoning and procedural complications | 1/51 | 9/51 | 10/102 |
| ContusionInjury, poisoning and procedural complications | 8/51 | 4/51 | 12/102 |
| PyrexiaGeneral disorders | 7/51 | 6/51 | 13/102 |
| VomitingGastrointestinal disorders | 4/51 | 7/51 | 11/102 |
| ExcoriationInjury, poisoning and procedural complications | 6/51 | 2/51 | 8/102 |
| Age, Continuous(Years) | Adults: LTG | Adolescents: LTG | Total |
|---|---|---|---|
| Mean | 29.0 ± 9.9 | 8.2 ± 4.1 | 18.6 ± 12.9 |
| Sex: Female, Male(Participants) | Adults: LTG | Adolescents: LTG | Total |
|---|---|---|---|
| Female | 23 | 25 | 48 |
| Male | 28 | 26 | 54 |
| Race/Ethnicity, Customized(participants) | Adults: LTG | Adolescents: LTG | Total |
|---|---|---|---|
| Asian-Japanese | 51 | 51 | 102 |
The record gives a start of Aug 2006, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamotrigine